Syneos Health
Accelerating Site Selection, Site Activations, and Patient Enrollment
Over the last 18 months, Syneos Health has been laser-focused on employing data and technology solutions to help biopharma customers solve their most complex clinical development challenges.
Earlier this year, Syneos Health announced a partnership with Microsoft to leverage AI-ready technology to speed asset development and optimize clinical development and commercial performance for biopharma customers. Syneos Health also announced a partnership with KX focused on delivering data-driven predictive analytics, AI, and machine learning capabilities. The company is using access to the industry’s first Data Timehouse, a new class of data and AI management engine designed for temporal data generated by digital transformation, to help customers address complex healthcare decisions. Lastly, in September 2023, the company announced it will expand its relationship with Oracle. Using the Oracle Cerner Learning Health Network (LHN) and elements of Oracle’s suite of study startup solutions, the companies are seeking to help reduce the time it takes to recruit patients for clinical studies and increase the diversity of patient populations participating in medical research.
Thanks to these partnerships and the company’s other innovative offerings and trial designs, Syneos Health is helping to deliver improved site selection, faster site activations, and accelerated patient enrollment. Through its novel clinical trial solutions, Syneos Health was able to more than double patient enrollment in just nine weeks for a study related to a COVID-19 clinical trial for high-risk populations that was significantly behind by deploying Digital Amplifier targeting digital outreach to HCPs within 60 miles of active trial sites.
